Sustainability at Biocon

...set up to deliver sustainable growth trajectory Biocon 1 Today BIOCON BIOLOGICS GROWTH DRIVERS < 2 years 2-4 years >4 years - - Pegfilgrastim - Trastuzumab - Bevacizumab (EU) Glargine 100 IU - Aspart (EU) Adalimumab (EU) - Etanercept (EU) - - Bevacizumab (US) Aspart (US) Adalimumab (US) -rH-Insulin (US) - Vaccines¹ (SILS collaboration) - Aflibercept² Ustekinumab Denosumab - Pertuzumab Glargine 300 IU Seven undisclosed programs 1 Subject to completion of the acquisition of Covishield Technologies Private Limited (CTPL); 2 Expected to be included in BBL portfolio post the completion of BBL's acquisition of Viatris' biosimilar business (Viatris has global rights to the program partnered with Momenta) 21

View entire presentation